Executive Team

Steven B. Engle

Mr. Engle was appointed chairman and chief executive officer in 2007. With more than 25 years of executive leadership and biotechnology and pharmaceutical industry experience, his expertise spans the areas of therapeutic products, operations and corporate development. He previously served as chairman of the board and chief executive officer of La Jolla Pharmaceutical Company, a publicly-held biopharmaceutical company focused on the research and development of therapeutic products for autoimmune and antibody-mediated diseases. He joined La Jolla Pharmaceutical Company in 1993, became president and a director in 1994, CEO in 1995, and chairman of the board in 1997. Prior to joining La Jolla, he held executive-level positions at Cygnus Therapeutic Systems, a developer of drug delivery systems, and Micro Power Systems, Inc., a manufacturer of high technology products, including medical devices. He began his professional career with the Strategic Decisions Group and the Stanford Research Institute. Mr. Engle is a graduate of the University of Texas with B.S. and M.S. degrees in biomedical engineering.

Patrick J. Scannon, M.D., Ph.D.

is XOMA's Company Founder, Executive Vice President, Chief Biotechnology Officer and a member of the Board of Directors of XOMA Ltd. Since 1980, Dr. Scannon has directed the Company's product identification, evaluation and clinical testing programs. As Chief Biotechnology Officer, he heads the clinical and preclinical research programs, evaluating several classes of biologic compounds and conducting clinical studies for infectious, oncologic and immunologic indications. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia. He completed his medical internship and residency at the Letterman Army Medical Center in San Francisco. A board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He has served as a Trustee of the University of California Berkeley Foundation and is a member of the University of California Berkeley Chancellor's Community Advisory Board. He has served or is serving on the boards of several companies and institutions, and is currently a member of the DSRC (Defense Sciences Research Council), an advisory board for DARPA (Defense Advanced Research Projects Agency) and also a member of the Department of Defense’s Threat Reduction Advisory Committee (TRAC), where he is Chair of the ChemBioWarfare Defense Panel. Dr. Scannon is inventor or co-inventor of several issued U.S. patents, and he has published numerous scientific abstracts and papers.

Mary L. Anderson

is Vice President, Business Development. Ms. Anderson joined XOMA in February 2008. She is responsible for overseeing XOMA's business development initiatives, including licensing activities related to XOMA's therapeutic pipeline, support of the antibody collaborations business, the licensing of the company's antibody technologies and the advancement of biodefense programs.

Ms. Anderson has 20 years of experience in the pharmaceutical and biotechnology industry. Prior to joining XOMA, she served as the Executive Director, Global Licensing and Business Development for Oncology at Merck-Serono, a global biopharmaceuticals company where she led the in-licensing of multiple clinical stage oncology products and was a key member of the team responsible for the approximately $15 billion acquisition of Serono SA.

Before her experience at Merck-Serono, Ms. Anderson was Senior Director, Corporate Development at MorphoSys, where she was charged with growing the antibody discovery business. She also held business development positions at Agensys and Bayer. Trained in biochemistry, Ms. Anderson spent her early years in research at Chiron and Gen-Probe. She received a master’s degree in business administration from St. Mary's College of California and a bachelor of science degree in biochemistry from California Polytechnic State University at San Luis Obispo.

Daniel P. Cafaro

is XOMA's Vice President, Regulatory Affairs and Compliance. Mr. Cafaro joined the Company in 1996 as Director of Regulatory Affairs. In addition to directing worldwide regulatory activities for the Company, he has had responsibility for leadership of several development programs including ophthalmic applications. From 1981 to 1996, Mr. Cafaro held several managerial positions at Allergan, Inc., directing worldwide regulatory affairs and product development. He belongs to several professional societies including the Regulatory Affairs Professional Society (RAPS), The Organisation for Professionals in Regulatory Affairs (TOPRA), and the Drug Information Association (DIA). Mr. Cafaro holds a B.S. in chemistry from the University of California Los Angeles.

Stephen K. Doberstein, Ph.D.

is Vice President of Research. Dr. Doberstein leads the Preclinical Research and Development organization at XOMA and is responsible for directing the discovery and development of XOMA's drug candidates, including antibody discovery, cell line development, and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics. Dr. Doberstein brings 15 years of experience in biotechnology research and development. Most recently, he was Vice President, Research at Five Prime Therapeutics, Inc., a protein and antibody discovery and development company. Prior to his position at Five Prime, he served as Vice President, Research, at Xencor, Inc., an antibody engineering and development company, where he was instrumental in advancing its protein platform technologies and preclinical product candidates.

Dr. Doberstein holds a Ph.D. in Biochemistry, and Cell and Molecular Biology from Johns Hopkins University School of Medicine and completed his postdoctoral work at UC Berkeley. He began his career as an Engineer at DuPont after earning his B.S. Ch.E. degree in Chemical Engineering from the University of Delaware.

Patricia Donahue

is Vice President, Collaborations Business. Ms. Donahue has more than 25 years of biotechnology and pharmaceutical industry experience. As leader of the Collaborations Business, she is responsible for the establishment, and management of the antibody discovery and development collaborations XOMA conducts with other biotechnology and pharmaceutical companies. She also supports product licensing and strategic business initiatives. In 2004, Ms. Donahue joined the Company as Director, Business Development, where she established the architecture for XOMA’s HE(TM) technology and antibody collaborations businesses. Previously, Pat held positions of increasing responsibility at Merck KGaA / EMD, Dey Labs and 3M Pharmaceuticals where she demonstrated cross-functional leadership while holding functional responsibility in new molecule research, clinical research, marketing and sales, program management and business to corporate development. While at 3M, she was a key member of the core teams bringing Tambocor® and Climara® from late stage clinical development to approval. Ms. Donahue holds a B.A. in biology and chemistry from Gustavus Adolphus College, St. Peter, MN and an M.B.A. from the University of St. Thomas, St. Paul, MN.

Christopher J. Margolin

is Vice President, General Counsel and Secretary of XOMA Ltd. and Secretary to the Board of Directors. He is responsible for the management of all legal matters affecting or involving the XOMA companies, including corporate governance, financings, intellectual property, licensing, litigation and mergers and acquisitions. Prior to joining the Company in 1991, Mr. Margolin was a corporate attorney holding several different positions including Assistant General Counsel at Raychem Corporation, an international high technology company, for 11 years. From 1975 to 1980, he was a division counsel for TRW and from 1972 to 1975, he was an associate at the law firm of McCutcheon, Black, Verleger and Shea in Los Angeles. A graduate of Princeton University, he holds a law degree from the University of Pennsylvania and an M.B.A. from the UCLA Graduate School of Management, and he is a member of the California and American Bar Associations.

Calvin L. McGoogan

Robert S. Tenerowicz

is Vice President, Operations. Mr. Tenerowicz joined XOMA in December 2004 and is responsible for XOMA's operations, which include project and alliance management, process development and manufacturing, and materials management/purchasing. Before joining XOMA, Mr.Tenerowicz was vice president of manufacturing and project management at GenVec, Inc. He has been working in the biotechnology industry since 1985 and brings over 20 years of biotechnology industry and product development experience which includes his time working for GenVec, Abgenix, Cell Genesys, and Genentech. Mr. Tenerowicz holds a B.S. in physiology from the University of California at Davis and an M.B.A. in operations management from Golden Gate University and is a member of the Keck Graduate Institute’s Amgen Bioprocessing Center Advisory Board.

Charles C. Wells

is Vice President, Human Resources and Information Technology. In this role, Mr. Wells is responsible for setting and implementing company’s Human Resources and Information Technology strategies. Prior to joining XOMA in May 2001, he served as Senior Vice President, Human Resources for Roche Pharmaceuticals, a position he held since 1995. During a career that spans more than 30 years, Mr. Wells has held human resources positions with Syntex Corporation (prior to the Roche acquisition), Epic Healthcare (a hospital management company), Frito Lay and Burlington Industries. In these various roles, he has been instrumental in the design and delivery of a number of key domestic and international change initiatives and processes that brought to fruition human resource strategies developed under his leadership. Mr. Wells holds a B.A. in Psychology from Pfeiffer University in Misenheimer, North Carolina. He is a member of the Society for Human Resources Management, the Northern California Human Resource Council, and the HR Strategic Issues Council.